Elena Rivolti

Reggio Nell'emilia, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Prognostic Impact of Chromosome 1q Gain/Amplification in Multiple Myeloma Treated With Daratumumab-Based Regimens.

Prognostic Impact of Chromosome 1q Gain/Amplification in Multiple Myeloma Treated With Daratumumab-Based Regimens.

Journal: European journal of haematology

Published: December 27, 2025

Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study.

Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study.

Journal: British journal of haematology

Published: March 31, 2025

Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial.

Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial.

Journal: The Lancet. Haematology

Published: January 30, 2025

Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study.

Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study.

Journal: Hematological oncology

Published: November 22, 2024

Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials.

Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials.

Journal: Haematologica

Published: September 15, 2024

Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature.

Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature.

Journal: Expert opinion on biological therapy

Published: May 17, 2024

Evans syndrome: Disease awareness and clinical management in a nation-wide ITP-NET survey.

Evans syndrome: Disease awareness and clinical management in a nation-wide ITP-NET survey.

Journal: European journal of haematology

Published: April 10, 2024

Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial.

Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial.

Journal: Blood advances

Published: June 20, 2023

Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study.

Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study.

Journal: American journal of hematology

Published: March 29, 2023

Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.

Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.

Journal: Annals of hematology

Published: August 05, 2021

Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study.

Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study.

Journal: Leukemia & lymphoma

Published: March 18, 2021

Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia.

Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia.

Journal: Blood

Published: January 14, 2021

Showing 1-12 of 14

Last Updated: 09/26/2026